Ann: February 2015 Newsletter, page-3

Hi Grantjo

Maria says that there are sufficient funds and antibody to complete cross tissuue reactivity study and the single dose toxicology studies leading to the pre-IND meeting .......... which I would read as the next value inflection point (read significant SP incrementation point).

I have been tracking the midkine research myself BUT news of an aptimer (FGF5S) to bind with FGF5, a deal with Kikkoman to produce FGF5S in bulk is extreme left field news. Progress towards serious scientific validation study of the new aptimer through Tokyo University would (subject to result) be a major value inflextion point.

cheers